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 We describe the case of an 85-year-old woman who developed 
acute confusion, acute kidney injury and temperature spikes 
while on extended courses of beta-lactams for osteomyelitis. 
The cause of her deterioration was felt to be due to sepsis 
when in fact it was as a result of toxicity from antibiotics. 
This was demonstrated by a rapid resolution in her condition 
following haemodialysis. We also performed a literature 
review to appraise the neuro- and nephrotoxicity of various 
antibiotics and how best to manage toxicity when it occurs. 
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 Case history 
 In September 2015, a fully lucid 85-year-old woman with 
type 2 diabetes, hypertension, peripheral vascular disease 
and previous right above knee amputation was admitted 
under the vascular team with an ischaemic, infected left foot. 
C-reactive protein and white blood cell count were 61 mg/L 
and 4.3×10 9 , respectively. Augmentin was started and on day 
3 of the admission, after failed angioplasty, she underwent 
a trans-metatarsal amputation. Following the surgery, on 
the basis of culture results, she was switched to intravenous 
ceftazidime 2 g three times a day with a plan to continue for 
6 weeks. However, 1 month into her hospital stay her creatinine 
rose above 100 µmol/L (previously 57 µmol/L) and by the end 
of October it had increased further to 210 µmol/L. Coincident 
with the rise in creatinine she became confused and febrile. 
Urinalysis, microscopy and cultures revealed 2+ of protein 
with no evidence of urine infection. She had normal sized 
kidneys with preserved cortico-medullary differentiation on 
ultrasound examination. Unenhanced computed tomography 
scan of the head was normal. C-reactive protein and white 
blood cell count were 24 mg/L (normal <5 mg/L) and 14.61×10 9 
(normal range: 3.5–11×10 9 ), respectively, at this point but were 
trending downwards ( Fig 1 ). The stump was clean and healing 
well. However, she continued to spike temperatures of up to 
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39°C that persisted for several days and prompted the addition 
of amoxicillin and then later temocillin and meropenem for 
presumed pneumonia despite no hypoxia and normal chest 
X-ray. 
 Her condition continued to worsen with her creatinine 
climbing to 350 µmol/L. Her Glasgow Coma Scale (GCS) score 
had deteriorated to 5/15 (E1, M3 V1). Muscle tone was normal 
throughout but occasional myoclonic jerks were observed 
bilaterally. Corneal reflexes and dolls eye movements were 
present. At this point, her general deterioration was deemed 
to be most likely a result of uncontrolled sepsis. However, an 
electroencephalogram (EEG) showed brain wave patterns 
suggestive of non-convulsive status epilepticus (NCSE). The 
possibility of beta-lactam toxicity was raised by the consulting 
nephrology team. Antibiotics were stopped and the patient 
underwent four sessions of haemodialysis. There was a steady 
and dramatic improvement in her GCS score and renal 
function ( Fig 1 ). 
 Discussion 
 Several of this patient's symptoms, particularly the swinging 
fevers, led those caring for her to believe that her deterioration 
was due to ongoing sepsis. While beta-lactam neurotoxicity 
is relatively well recognised it was overlooked in this clinical 
setting until quite late in the course of her illness. This case 
highlights several learning points of interest to all those 
involved in caring for patients receiving antibiotics. 
 The effects of beta-lactams on the central nervous system 
(CNS) have been known since the 1940s when classic 
experiments by Walker  et al on macaque monkeys showed 
that injecting penicillin into their cerebral cortex left them 
listless and uninterested in their surroundings. 1 In humans, 
the clinical manifestations of toxicity include confusion, 
disorientation, twitching, somnolence, myoclonus and 
convulsions. 2,3 The mechanism of action of beta-lactam 
neurotoxicity is thought to be the antagonistic action of 
the beta-lactam ring on the GABA receptor in the brain. 
As GABA is the main inhibitory neurotransmitter in the 
brain, its inhibition results in CNS excitation and seizures. 
Cephalosporins, like penicillins, contain a beta-lactam ring 
and are thus also associated with neurotoxicity. 4 Among the 
cephalosporins, ceftazidime is considered to be particularly 
prone to causing CNS disturbances. 5 In one series, the 
incidence of seizures with ceftazidime was reported to be as 
high as 3 in 1,000 patients. 6 The mean daily dose for those 
developing neurotoxicity was 4 g and EEG evidence of NCSE 
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was found in 75% of patients where it was performed. 6 
Myoclonus was reported in 50%. Background renal dysfunction 
and prior CNS lesions are known to add to the risk of antibiotic 
induced seizures. 7,8 The time to developing encephalopathy 
from starting a cephalosporin has been reported as between 
1 and 10 days. 9 Our patient had been on ceftazidime for nearly 
1 month before any confusion was noted. However, once she 
developed renal dysfunction the confusion ensued very quickly. 
Ceftazidime is exclusively renally excreted and the half-life of 
the drug increases significantly as glomerular filtration rate 
(GFR) decreases. 10 This patient's ceftazidime dose was not 
decreased as she developed acute kidney injury and thus it is 
likely increased drug levels resulted in or exacerbated the CNS 
toxicity. 
 Some beta-lactams are known to be directly nephrotoxic 
causing acute tubular necrosis affecting the proximal tubule, 
particularly if intracellular drug concentrations are high. 11 
Cephaloridine is actively transported into the proximal 
tubular cells via the baso-lateral membrane and there is little 
secretion into the lumen on the apical side, which results 
in high intracellular concentrations; this puts it among the 
most nephrotoxic beta-lactams. 11 Ceftazidime on the other 
hand does not accumulate in tubular luminal cells in high 
concentrations and thus is not traditionally associated with 
nephrotoxicity. Even so, clinical studies have shown that 
ceftazidime can in fact result in renal impairment. In one study, 
the authors showed that GFR, as measured by EDTA clearance, 
fell by a mean of 9.6 mL/min during treatment with ceftazidime 
despite serum creatinine remaining unchanged. In the group 
of patients with estimated GFR of less than 30 mL/ min at 
the start of therapy, the effects on kidney function were 
even more pronounced. 12 Another study has shown that the 
incidence of acute kidney injury increases with the number 
of potentially nephrotoxic drugs a patient is exposed to, and 
our patient had several courses of antibiotics that may have 
cumulatively worsened the toxic effects. 13 It is also possible 
that intravenous contrast administered in the first days of her 
admission during attempts to salvage the limb contributed to 
her renal dysfunction but the timing of the acute kidney injury 
would not support this. 14 Finally, this patient had nominally 
normal kidney function on admission but had had a previous 
above knee amputation so had reduced muscle mass. Thus, 
her estimated GFR may have overestimated her true kidney 
function and belied her risk of developing renal toxicity with 
ceftazidime. Acute interstitial nephritis has also been reported 
with ceftazidime but there was little evidence for this with no 
rash or eosinophilia and a quick recovery following dialysis 
(albeit with concomitant drug cessation). 15 
 Swinging temperatures are also a well-recognised feature of 
beta-lactam drugs. 16 The timing of onset of the fevers related 
to beta-lactams has been reported at a median of 8 days after 
starting the offending drug but can occur after weeks to several 
months later. 16 As in this case, drug fever can result in clinical 
confusion. The inflammatory markers were only modestly 
elevated and were declining ( Fig 1 ) despite the very high spiking 
temperatures and there was no convincing source of sepsis. Thus, 
in retrospect, the picture was much more typical of drug toxicity. 
 Grill and Maganti have suggested that EEG may be useful 
in detecting drug-induced NCSE in patients developing 
encephalopathy on potentially neurotoxic medications. 5 The 
finding of NCSE should prompt the immediate cessation of any 
possible offending drug and anti-epileptic medications may 
be required, at least temporarily. In normal renal function, 
stopping the cephalosporin should bring about resolution of 
encephalopathy in 2–7 days; however, Grill and Maganti still 
recommend that haemodialysis or hemofiltration be considered 
in those who have renal impairment. 5 A number of factors 
determine how dialysable any particular drug is, including 
the degree of protein binding and molecular weight. 17 Only 
the unbound fraction is available for diffusion across dialysis 
membranes. As the molecular weight of a drug increases, 
diffusion of the drug across a membrane progressively 
decreases; this means that large drugs like vancomycin are 
relatively poorly removed by dialysis. 18 Ceftazidime, which has 
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 Fig 1.  Blood test results and 
 patient’s temperature over 
time. Antibiotic courses are dis-
played in solid bars at the bottom 
of the graph. Amox = amoxicillin; 
CRP = C-reactive protein; HD = 
haemodialysis session; Mero = 
meropenem; Temo = temocillin; 
Temp = temperature. 
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a relatively low molecular weight of 636.6 Daltons and is 90% 
unbounded, is very effectively removed by dialysis. 19 
 This case serves to remind clinicians of the potentially toxic 
effects of beta-lactam antibiotics, especially in the context of 
renal failure. It also highlights that not all fevers are caused by 
infection but can be a consequence of the antibiotics used to 
treat them. Further, it demonstrates why a deteriorating patient, 
even in the presence of improving markers of infection, should 
prompt consideration of drug toxicity. Beta-lactam toxicity 
can be treated very effectively by withholding the drug and, 
if appropriate, initiating intensive haemodialysis. Extreme 
vigilance is important when prescribing antibiotics and dose 
adjustments are imperative when chronic kidney disease is 
present or acute kidney injury has occurred. 
 Key points 
 >  Risk factors for beta-lactam neurotoxicity include renal 
impairment and prior CNS lesions. 
 >  Swinging fevers can be a feature of beta-lactam toxicity 
occurring a median of 8 days after starting the drug. 
 >  Development of acute kidney injury in a patient on beta-
lactams should prompt consideration of dose reduction to 
prevent toxicity. 
 >  EEG can be useful to detect NCSE in patients suspected of 
having drug-induced encephalopathy. 
 >  The fi nding of beta-lactam induced encephalopathy should 
prompt immediate cessation of the offending drug and 
consideration of haemodialysis. ■ 
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